Tags

Type your tag names separated by a space and hit enter

Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
Pediatrics. 1996 May; 97(5):653-7.Ped

Abstract

OBJECTIVES

The goals of this study were to evaluate the proportion of previously vaccinated human immunodeficiency virus (HIV) type 1-infected children with detectable postvaccination measles antibody; to assess risk factors for vaccine failure; and to evaluate the response to reimmunization.

METHODS

A total of 81 perinatally HIV-infected children receiving medical care in the Bronx, New York who had previously received measles vaccine were enrolled. The Centers for Disease Control and Prevention (CDC) HIV class, lymphocyte subsets, and measles antibody were determined upon enrollment. Additional data abstracted from medical records included dates and number of prior measles vaccinations and CDC HIV class at the time of vaccination. Measles antibody was determined by microneutralization enzyme-linked immunosorbent assay (ELISA).

RESULTS

The median age at time of study was 42 months (range, 9 to 168 months). Overall, 58 (72%) subjects had detectable measles antibody (microneutralization ELISA titer > 1:5). Children studied within 1 year of vaccination were more likely to have detectable measles antibody than children evaluated more than 1 year after vaccination (83% vs 52%, P < .01). The proportion of children with detectable measles antibody was higher among children with no or moderate immunosuppression compared to those with severe immunosuppression when immune status was based on CD4%. Children vaccinated at 6 to 11 months of age appeared to have a higher proportion of detectable measles antibody than those who received a first measles vaccination after age 1. Only 1 (14%) of 7 previously vaccinated children who were seronegative or had very low titers experienced a four-fold rise in measles antibody when reimmunized.

CONCLUSION

These results support current recommendations to vaccinate HIV-infected children against measles. The proportion of children with detectable measles antibody among vaccinated HIV-infected children is considerably lower than in vaccinated healthy children. HIV-infected children may respond better to measles vaccine when it is administered before the first birthday. From our limited data it appears that reimmunization of previously vaccinated HIV-infected children with moderate to severe immunosuppression does not result in an antibody recall response.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Arpadi SM
Bronx-Lebanon Hospital Center, USA.
Markowitz LE
No affiliation info available
Baughman AL
No affiliation info available
Shah K
No affiliation info available
Adam H
No affiliation info available
Wiznia A
No affiliation info available
Lambert G
No affiliation info available
Dobroszycki J
No affiliation info available
Heath JL
No affiliation info available
Bellini WJ
No affiliation info available

MeSH

AdolescentAge FactorsAntibodies, ViralChildChild, PreschoolEnzyme-Linked Immunosorbent AssayHIV InfectionsHIV-1HumansImmune ToleranceImmunization, SecondaryImmunocompromised HostInfantLymphocyte SubsetsMeasles VaccineMeasles virusNeutralization TestsNew York CityRisk FactorsTime FactorsVaccination

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8628602

Citation

Arpadi, S M., et al. "Measles Antibody in Vaccinated Human Immunodeficiency Virus Type 1-infected Children." Pediatrics, vol. 97, no. 5, 1996, pp. 653-7.
Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics. 1996;97(5):653-7.
Arpadi, S. M., Markowitz, L. E., Baughman, A. L., Shah, K., Adam, H., Wiznia, A., Lambert, G., Dobroszycki, J., Heath, J. L., & Bellini, W. J. (1996). Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics, 97(5), 653-7.
Arpadi SM, et al. Measles Antibody in Vaccinated Human Immunodeficiency Virus Type 1-infected Children. Pediatrics. 1996;97(5):653-7. PubMed PMID: 8628602.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. AU - Arpadi,S M, AU - Markowitz,L E, AU - Baughman,A L, AU - Shah,K, AU - Adam,H, AU - Wiznia,A, AU - Lambert,G, AU - Dobroszycki,J, AU - Heath,J L, AU - Bellini,W J, PY - 1996/5/1/pubmed PY - 1996/5/1/medline PY - 1996/5/1/entrez SP - 653 EP - 7 JF - Pediatrics JO - Pediatrics VL - 97 IS - 5 N2 - OBJECTIVES: The goals of this study were to evaluate the proportion of previously vaccinated human immunodeficiency virus (HIV) type 1-infected children with detectable postvaccination measles antibody; to assess risk factors for vaccine failure; and to evaluate the response to reimmunization. METHODS: A total of 81 perinatally HIV-infected children receiving medical care in the Bronx, New York who had previously received measles vaccine were enrolled. The Centers for Disease Control and Prevention (CDC) HIV class, lymphocyte subsets, and measles antibody were determined upon enrollment. Additional data abstracted from medical records included dates and number of prior measles vaccinations and CDC HIV class at the time of vaccination. Measles antibody was determined by microneutralization enzyme-linked immunosorbent assay (ELISA). RESULTS: The median age at time of study was 42 months (range, 9 to 168 months). Overall, 58 (72%) subjects had detectable measles antibody (microneutralization ELISA titer > 1:5). Children studied within 1 year of vaccination were more likely to have detectable measles antibody than children evaluated more than 1 year after vaccination (83% vs 52%, P < .01). The proportion of children with detectable measles antibody was higher among children with no or moderate immunosuppression compared to those with severe immunosuppression when immune status was based on CD4%. Children vaccinated at 6 to 11 months of age appeared to have a higher proportion of detectable measles antibody than those who received a first measles vaccination after age 1. Only 1 (14%) of 7 previously vaccinated children who were seronegative or had very low titers experienced a four-fold rise in measles antibody when reimmunized. CONCLUSION: These results support current recommendations to vaccinate HIV-infected children against measles. The proportion of children with detectable measles antibody among vaccinated HIV-infected children is considerably lower than in vaccinated healthy children. HIV-infected children may respond better to measles vaccine when it is administered before the first birthday. From our limited data it appears that reimmunization of previously vaccinated HIV-infected children with moderate to severe immunosuppression does not result in an antibody recall response. SN - 0031-4005 UR - https://www.unboundmedicine.com/medline/citation/8628602/Measles_antibody_in_vaccinated_human_immunodeficiency_virus_type_1_infected_children_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&amp;pmid=8628602 DB - PRIME DP - Unbound Medicine ER -